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Acute myeloid leukemia in a father and son
with a germline mutation of ASXL1
Karen Seiter1* , Kyaw Htun1, Paul Baskind1 and Zach Liu2

Abstract
Background: Myelodysplastic syndromes and acute myeloid leukemia usually occur sporadically in older adults.
More recently cases of familial acute myeloid leukemia and/or myelodysplastic syndrome have been reported.
Case presentation: Currently we report a father and son who both developed myelodysplastic syndrome that
progressed to acute myeloid leukemia. Both patients were found to have the identical mutation of ASXL1 on nextgen
sequencing of both hematologic and nonhematologic tissues.
Conclusions: These cases support the diagnosis of a germline mutation of ASXL1.
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Background
Myelodysplastic syndromes and acute myeloid leukemia
usually occur sporadically in older adults. These diseases
also occur in younger patients with congenital syndromes such as Fanconi anemia, dyskeratosis congenita,
and severe congenital neutropenia [1, 2]. More recently
cases of familial acute myeloid leukemia (AML) and/or
myelodysplastic syndrome (MDS) have been reported
with mutations in RUNX1, CEBPA, GATA2, ANKRD26,
SRP72, DDX41 or ETV6 [1, 2]. Currently we report a
father and son who both developed MDS to AML. Both
patients were found to have the identical mutation of
ASXL1 on nextgen sequencing. The presence of the
mutation in nonhematologic tissues supports the diagnosis of a germline mutation of ASXL1.
Case presentation
Son

A 46 year old man with no prior medical history
was referred to us for evaluation of leucopenia and
thrombocytopenia in June of 2012. The white blood
count was 3200/mm3 with 51% neutrophils, 46%
lymphocytes, 2% monocytes and 1% eosinophils. The
hemoglobin was 13.1 g/dl and the platelet count was
103,000/mm3. The bone marrow was normocellular with

20% blasts and megakaryocytic dysplasia. Flow cytometry
demonstrated that the immunophenotype was CD13,
CD33, CD11c, CD34, CD117, HLA-DR, CD71, CD41
(very dim), CD38, and CD9 (dim). Cytogenetics were
normal, however only 4 metaphases were obtained. AML
and MDS fluorescence in-situ hybridization (FISH) panels
were normal. A diagnosis of high grade MDS evolving to
AML was made.
The patient received induction therapy with high dose
cytarabine, high dose mitoxantrone, and etoposide. Bone
marrow evaluation upon count recovery showed a
hypercellular marrow with 5% myeloblasts and dysplastic
features, including pseudo-Pelger-Huet cells and dyserthropoiesis. The patient received a second cycle of
chemotherapy with high dose cytarabine. The bone
marrow then showed a normocellular marrow with
maturing trilineage hematopoiesis, dyserthropoiesis
and 1% blasts.
In September 2012 the patient underwent an allogeneic
stem cell transplant using a fludarabine, melphalan,
busulfan conditioning regimen and peripheral blood
stem cells from his HLA identical sister. He has
remained well, with full donor engraftment, for the
past 3.5 years.
Father
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In September 2016 the patient’s 75 year old father presented to us. He had been diagnosed with MDS elsewhere
in January 2012. The initial bone marrow demonstrated
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5% blasts and normal cytogenetics. He had received
decitabine for 4.5 years. The patient was referred to us
after his blood counts had worsened. The white blood
count was 2900/mm3 with 56% neutrophils, 42% lymphocytes, 1% monocytes, and 1% eosinophils. The hemoglobin
was 9.6 g/dl and the platelet count was 28,000/mm3. Bone
marrow evaluation demonstrated AML with MDS-related
changes, with 26% blasts and an immunophenotype of
CD13, CD33, CD34, CD117, and HLA-DR. Cytogenetics
were complex with 44,XY,-3,del(5)(q13q31),add(9)(q13),10,der(16)t(9;16)(q13;q11.2),-17,+ 21[7]/46,XY[6]. Mutations
in FLT3 and NPM were not detected on PCR. The patient
received CLAG-idarubicin chemotherapy but had refractory disease. He then opted for hospice care and expired
shortly thereafter.
Nextgen sequencing was performed on the diagnostic
bone marrow sample and a buccal swab from the father,
and on peripheral blood, buccal swab, skin biopsy and
archived bone marrow from the son. Genomic DNA was
extracted and purified. Targeted sequencing was performed
by using a combination of multiplexed PCR (AmpliSeq
Hotspot primers) to generate libraries. Adapters were then
ligated to the PCR products, where the sequences were
tagged with specific barcodes. The barcoded libraries were
then clonally amplified using emulsion PCR (emPCR). The
emPCR was then purified using magnetic bead purification
followed by semiconductor-based sequencing on an Ion
Torrent PGM (Life Technology). The targeted gene panel
developed in this laboratory includes the following 32
genes: ABL1, ASXL1, BRAF, CBL, CDKN2A, CEBPA,
CREBBP, CSF1R, DNMT3A, ETV6, EZH2, FBXW7, FLT3,
HRAS, IDH1, IDH2, JAK3, KIT, KRAS, NORCH1, NPM1,
NRAS, PDGFRA, PHF6, PTEN, RUNX1, SF3B1, SRSF2,
TET2, TP53, U2AF1, and WT1. Each variant was
analyzed manually using variant caller from Ion Torrent
software (Life Technology) and cross-referenced with
Ingenuity(tm) software (Qiagen) for bioinformatics.
Evidence based categorization of the variants were
performed by genomic analysis software (GenomOncology).
This test is designed to detect alterations in genes
that are clinically known to play a role in tumor
genesis and provide prognostic value. For each gene,
the minimum required coverage is 500 sequence reads
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based on bidirectional sequencing. The minimum acceptable frequency is 5%.
Both patients were enrolled on a clinical trial of
familial leukemias that was approved by the Committee
on the Protection of Human Subjects at New York
Medical College. Both specifically consented to genetic
testing. These included consent for publication.
Results of nextgen sequencing are summarized in
Table 1. The father’s diagnostic bone marrow demonstrated
a mutation in ASXL1 (c.2957A > G; p.N986S) with an
allelic frequency of 50%. In addition a mutation in TP53
was detected with an allelic frequency of 12%. A buccal
swab identified the same ASXL1 mutation at a frequency of
49.4%. We then tested the patient’s son for the same
panel of mutations. His peripheral blood did not
exhibit any mutations, however the blood was derived
from his healthy sister (100% XX by FISH at the time
of peripheral blood nextgen sequencing). A buccal
swab on the son demonstrated the identical ASXL1
mutation (c.2957A > G; p.N986S) at a frequency of
21.7%. A skin biopsy demonstrated this mutation at a
frequency of 41.6% and his archived first post chemotherapy
bone marrow (with 5% blasts) demonstrated the mutation
at a frequency of 50.5%.

Discussion and conclusions
Constitutive mutations of ASXL1 occur in the BohringOpitz syndrome, a rare condition characterized by facial
anomalies, multiple malformations, severe intellectual
disabilities and early death [3]. Somatic mutations of
ASXL1 were first reported in patients with hematologic
malignancies in 2009 [4]. Subsequent studies have since
shown that mutations in ASXL1 occur in approximately
6% to 30% of patients with AML and in 15 to 20% of
patients with MDS [5–7]. These mutations are more
common in older patients and are more common in
patients with secondary rather than de novo AML [8].
Mutations in ASXL1 have an adverse effect on survival
in both MDS and AML [5, 9, 10].
In a mouse model developed by Abdel-Wahab, mice
with germline complete deletion of ASXL1 (ASXL1−/−)
were no longer viable by day 19.5 and exhibited microphthalmia/anophthalmia, cleft palates and multiple skeletal

Table 1 Nextgen sequencing results
Patient

Date

Source

Gene

Mutation

Allelic burden

Father

9/20/2016

Bone marrow

TP53
ASXL1

c.675delT; p.G226 fs
c.2957A > G; p.N986S

12.0%
50.0%

10/26/2016

Buccal swab

ASXL1

c.2957A > G; p.N986S

49.4%

7/17/2012

Bone marrow (5% blasts)

ASXL1

c.2957A > G; p.N986S

50.5%

11/4/2016

Buccal swab

ASXL1

c.2957A > G; p.N986S

21.7%

12/09/2016

Peripheral blood (100% donor)

Normal

1/13/2017

Skin biopsy

ASXL1

c.2957A > G; p.N986S

41.6%

Son
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abnormalities [11]. Mice with hematopoietic –specific
deletion of ASXL1 developed progressive leucopenia
and anemia that was accompanied by an increase in
erythroid precursor cells in both the bone marrow
and spleen. Wang also reported that ASXL1−/− mice
had developmental abnormalities including dwarfisim,
anophthalmia, and 80% embryonic lethality [12]. Surviving
mice developed features of MDS. In this model, ASXL1+/−
mice also developed an MDS-like phenotype indicating a
haploinsufficient effect of ASXL1 in the pathogenesis of
myeloid malignancies.
ASXL1 mutations have been reported in a limited
number of patients with familial hematologic malignancies.
Somatic mutation of ASXL1 was reported in a patient with
chronic myelomonocytic leukemia in the setting of a
germline mutation in ANKRD26 [13]. Somatic mutations
of ASXL1 have also been reported in patients with
germline mutations of GATA2 [14]. Hamadou described
two sisters with NHL who were noted to have a presumed
germline ASXL1 mutation in peripheral blood samples
performed when they were in remission [15]. The sisters’
healthy mother and brother also carried this mutation.
Our two patients shared the identical ASXL1 mutation in multiple tissues. This specific mutation
(c.2957A > G; p.N986S) has been reported in one case
of Bohring-Opitz syndrome in the National Center for
Biotechnology Information database. Its significance in
hematologic malignancies to date is unclear, however
it is a missense mutation in exon 12, a site of other
known pathogenetic mutations in ASXL1 in hematologic
malignancies14. Both patients were similar to the heterozygous mouse models in that their hematologic malignancies occurred after a prolonged latency period. The
son’s earlier development of MDS/AML could be an
example of anticipation, as is often seen in hereditary
cancer syndromes. We believe this is the first reported
case of a germline mutation of ASXL1 in association with
MDS and AML.
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